|Bid||467.63 x 800|
|Ask||469.64 x 1400|
|Day's range||464.80 - 477.41|
|52-week range||344.63 - 670.62|
|Beta (5Y monthly)||0.90|
|PE ratio (TTM)||N/A|
|Earnings date||16 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||591.00|
Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.
HERCULES, Calif., January 06, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the fourth quarter and full year 2022 on Thursday, February 16, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.